Transparency Market Research (TMR) has published a new report titled, “Pulmonary Drug Delivery Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global pulmonary drug delivery devices market was valued at US$ 35,000 Mn in 2017 and is projected to expand at a CAGR of around 3.0% from 2018 to 2026. The report suggests that increase in prevalence and incidence of respiratory diseases and rise in prescription of combination therapies are anticipated to boost the global pulmonary drug delivery devices market from 2018 to 2026.
North America and Europe are expected to dominate the global pulmonary drug delivery devices market in the next few years. This is attributed to well-established health care infrastructure coupled with high demand for superior-quality drugs and devices. Players operating in the global pulmonary drug delivery devices market are entering into distribution agreements in order to strengthen their footprint across the globe.
In 2016, Boehringer Ingelheim Pharmaceuticals, Inc. and HealthPrize Technologies launched RespiPoints, a free online program that educates, engages, and rewards people who are treating their COPD with Boehringer’s SPIRIVA RESPIMAT. Additionally, AstraZeneca entered into an agreement with ‘Cilag GmbH International’, an affiliate of Johnson & Johnson, for the divestment of the rights to Rhinocort Aqua (nasal spray indicated for allergic and non-allergic rhinitis) outside the U.S., in October 2016.
Request to View Sample of Report -
The report offers detailed segmentation of the global pulmonary drug delivery devices market. Based on product, the dry powder inhaler segment is likely to account for a prominent share of the market by 2026. Furthermore, the dry powder inhaler segment has been sub-segmented into single dose inhaler sub-segment and multi-dose inhaler sub-segment. The single dose inhaler sub-segment accounted for a higher share of the dry powder inhaler segment, as compared to multi-dose inhaler sub-segment, in 2017. Easy long-term use of devices is likely to propel the single dose inhaler sub-segment in the near future.
The metered-dose inhaler segment followed the dry powder inhaler segment, in terms of market share, in 2017. It was followed by the nebulizers segment. Low price and high requirement of manually-actuated pressurized inhalers for the treatment of asthma are expected to boost the metered-dose inhaler segment during the forecast period.
The asthma segment accounted for a prominent share of the market in 2017, followed by COPD, others, and cystic fibrosis segments. The cystic fibrosis segment is anticipated to expand at a high CAGR during the forecast period. Cystic fibrosis is not a curable disease, and it gets worse with age. Moreover, the diagnostic rate is significantly low. However, expansion of health care infrastructure and diagnostic facilities is expected to propel the segment.
The retail pharmacies segment held a significant share of the market in 2017, followed by hospital pharmacies and e-commerce segments. However, the e-commerce segment is anticipated to expand at a prominent CAGR in the near future, owing to entry of low cost generics and increasing awareness about mail-order pharmacies.
Comments
Post a Comment